Generic placeholder image

Current Neuropharmacology

Editor-in-Chief

ISSN (Print): 1570-159X
ISSN (Online): 1875-6190

Research Article

Bibliometric Analysis of the Research Status and Global Trends in Behavioral and Psychological Symptoms of Dementia in Alzheimer’s Disease from 2002 to 2022

Author(s): Haipeng Cai, Ruonan Du, Kebing Yang, Wei Li and Zhiren Wang*

Volume 22, Issue 10, 2024

Published on: 24 August, 2023

Page: [1720 - 1732] Pages: 13

DOI: 10.2174/1570159X21666230807144750

Price: $65

conference banner
Abstract

Background: Several reviews on behavioral and psychological symptoms (BPSDs) in patients with Alzheimer’s disease (AD) have summarized the current state of this field, but global trends are unclear.

Objective: This study utilized CiteSpace to provide a global overview of the current state of research on AD and its BPSDs and to predict future research trends in the field.

Methods: Data were retrieved from the Web of Science Core Collection. Bibliometric and cooccurrence analyses were performed using CiteSpace software. In total, 787 valid publications were included in the analysis.

Results: Publications on AD and BPSD have shown an increasing trend since 2002. The United States and the University of Toronto were the countries and institutions with the highest total number of publications, respectively. Japan and China were the second and third most influential in the field. Clive Ballard was the top author in terms of the number of publications. Journal of Alzheimer's Disease had the highest number of publications on this topic. Co-occurrence analysis showed that AD, behavioral symptoms, cognitive impairment, and early markers are hot topics in this area. Non-drug management of BPSDs, pharmacological treatment, and physiotherapy will be a hot topic in this field in the future.

Conclusion: Our study visualized the relevant articles over the past 21 years to detect global hotspots and trends. Our findings may help researchers to identify research hotspots in this field and will help in the selection of appropriate research topics, while possibly leading to cross-regional cooperation.

Graphical Abstract

[1]
Gulisano, W.; Maugeri, D.; Baltrons, M.A.; Fà, M.; Amato, A.; Palmeri, A.; D’Adamio, L.; Grassi, C.; Devanand, D.P.; Honig, L.S.; Puzzo, D.; Arancio, O. Role of Amyloid-β and Tau Proteins in Alzheimer’s Disease: Confuting the amyloid cascade. J. Alzheimers Dis., 2018, 64(s1), S611-S631.
[http://dx.doi.org/10.3233/JAD-179935] [PMID: 29865055]
[2]
Livingston, G.; Huntley, J.; Sommerlad, A.; Ames, D.; Ballard, C.; Banerjee, S.; Brayne, C.; Burns, A.; Cohen-Mansfield, J.; Cooper, C.; Costafreda, S.G.; Dias, A.; Fox, N.; Gitlin, L.N.; Howard, R.; Kales, H.C.; Kivimäki, M.; Larson, E.B.; Ogunniyi, A.; Orgeta, V.; Ritchie, K.; Rockwood, K.; Sampson, E.L.; Samus, Q.; Schneider, L.S.; Selbæk, G.; Teri, L.; Mukadam, N. Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. Lancet, 2020, 396(10248), 413-446.
[http://dx.doi.org/10.1016/S0140-6736(20)30367-6] [PMID: 32738937]
[3]
Supporting informal caregivers of people living with dementia. 2017. Available from: http://www.who.int/mental_health/neurology/dementia/dementia_the maticbrief_informal_care.pdf
[4]
Querfurth, H.W.; LaFerla, F.M. Alzheimer’s Disease. N. Engl. J. Med., 2010, 362(4), 329-344.
[http://dx.doi.org/10.1056/NEJMra0909142] [PMID: 20107219]
[5]
Scheltens, P.; Blennow, K.; Breteler, M.M.B.; de Strooper, B.; Frisoni, G.B.; Salloway, S.; Van der Flier, W.M. Alzheimer’s disease. Lancet, 2016, 388(10043), 505-517.
[http://dx.doi.org/10.1016/S0140-6736(15)01124-1] [PMID: 26921134]
[6]
Sun, Y.; Ma, C.; Sun, H.; Wang, H.; Peng, W.; Zhou, Z.; Wang, H.; Pi, C.; Shi, Y.; He, X. Metabolism: A novel shared link between diabetes mellitus and Alzheimer’s Disease. J. Diabetes Res., 2020, 2020, 1-12.
[http://dx.doi.org/10.1155/2020/4981814] [PMID: 32083135]
[7]
Zhao, Q.F.; Tan, L.; Wang, H.F.; Jiang, T.; Tan, M.S.; Tan, L.; Xu, W.; Li, J.Q.; Wang, J.; Lai, T.J.; Yu, J.T. The prevalence of neuropsychiatric symptoms in Alzheimer’s disease: Systematic review and meta-analysis. J. Affect. Disord., 2016, 190, 264-271.
[http://dx.doi.org/10.1016/j.jad.2015.09.069]
[8]
Joling, K.J.; O’Dwyer, S.T.; Hertogh, C.M.P.M.; van Hout, H.P.J. The occurrence and persistence of thoughts of suicide, self-harm and death in family caregivers of people with dementia: A longitudinal data analysis over 2 years. Int. J. Geriatr. Psychiatry, 2018, 33(2), 263-270.
[http://dx.doi.org/10.1002/gps.4708] [PMID: 28379646]
[9]
Dyer, S.M.; Harrison, S.L.; Laver, K.; Whitehead, C.; Crotty, M. An overview of systematic reviews of pharmacological and non-pharmacological interventions for the treatment of behavioral and psychological symptoms of dementia. Int. Psychogeriatr., 2018, 30(3), 295-309.
[http://dx.doi.org/10.1017/S1041610217002344] [PMID: 29143695]
[10]
Kouloutbani, K.; Venetsanou, F.; Markati, A.; Karteroliotis, K.E.; Politis, A. The effectiveness of physical exercise interventions in the management of neuropsychiatric symptoms in dementia patients: A systematic review. Int. Psychogeriatr., 2022, 34(2), 177-190.
[http://dx.doi.org/10.1017/S1041610221000193] [PMID: 33818342]
[11]
Azermai, M. Dealing with behavioral and psychological symptoms of dementia: A general overview. Psychol. Res. Behav. Manag., 2015, 8, 181-185.
[http://dx.doi.org/10.2147/PRBM.S44775] [PMID: 26170729]
[12]
Dimitriou, T.D.; Verykouki, E.; Papatriantafyllou, J.; Konsta, A.; Kazis, D.; Tsolaki, M. Non-Pharmacological interventions for the anxiety in patients with dementia. A cross-over randomised controlled trial. Behav. Brain Res., 2020, 390, 112617.
[http://dx.doi.org/10.1016/j.bbr.2020.112617] [PMID: 32428636]
[13]
Pritchard, A. Statistical bibliography or bibliometrics. J. Doc., 1969, (25), 348-349.
[14]
Donthu, N.; Kumar, S.; Mukherjee, D.; Pandey, N.; Lim, W.M. How to conduct a bibliometric analysis: An overview and guidelines. J. Bus. Res., 2021, 133, 285-296.
[http://dx.doi.org/10.1016/j.jbusres.2021.04.070]
[15]
Kokol, P.; Blažun Vošner, H.; Završnik, J. Application of bibliometrics in medicine: A historical bibliometrics analysis. Health Info. Libr. J., 2021, 38(2), 125-138.
[http://dx.doi.org/10.1111/hir.12295] [PMID: 31995273]
[16]
Tampi, R.R.; Bhattacharya, G.; Marpuri, P. Managing Behavioral and Psychological Symptoms of Dementia (BPSD) in the era of boxed warnings. Curr. Psychiatry Rep., 2022, 24(9), 431-440.
[http://dx.doi.org/10.1007/s11920-022-01347-y] [PMID: 35781675]
[17]
Abraha, I.; Rimland, J.M.; Trotta, F.M.; Dell’Aquila, G.; Cruz-Jentoft, A.; Petrovic, M.; Gudmundsson, A.; Soiza, R.; O’Mahony, D.; Guaita, A.; Cherubini, A. Systematic review of systematic reviews of non-pharmacological interventions to treat behavioural disturbances in older patients with dementia. The SENATOR-OnTop series. BMJ Open, 2017, 7(3), e012759.
[http://dx.doi.org/10.1136/bmjopen-2016-012759] [PMID: 28302633]
[18]
Calsolaro, V.; Femminella, G.D.; Rogani, S.; Esposito, S.; Franchi, R.; Okoye, C.; Rengo, G.; Monzani, F. Behavioral and psychological symptoms in dementia (BPSD) and the use of antipsychotics. Pharmaceuticals, 2021, 14(3), 246.
[http://dx.doi.org/10.3390/ph14030246] [PMID: 33803277]
[19]
Kales, H.C.; Lyketsos, C.G.; Miller, E.M.; Ballard, C. Management of behavioral and psychological symptoms in people with Alzheimer’s disease: An international Delphi consensus. Int. Psychogeriatr., 2019, 31(1), 83-90.
[http://dx.doi.org/10.1017/S1041610218000534] [PMID: 30068400]
[20]
Bessey, L.J.; Walaszek, A. Management of behavioral and psychological symptoms of dementia. Curr. Psychiatry Rep., 2019, 21(8), 66.
[http://dx.doi.org/10.1007/s11920-019-1049-5] [PMID: 31264056]
[21]
Davies, S.J.C.; Burhan, A.M.; Kim, D.; Gerretsen, P.; Graff-Guerrero, A.; Woo, V.L.; Kumar, S.; Colman, S.; Pollock, B.G.; Mulsant, B.H.; Rajji, T.K. Sequential drug treatment algorithm for agitation and aggression in Alzheimer’s and mixed dementia. J. Psychopharmacol., 2018, 32(5), 509-523.
[http://dx.doi.org/10.1177/0269881117744996] [PMID: 29338602]
[22]
Ballard, C.; Banister, C.; Khan, Z.; Cummings, J.; Demos, G.; Coate, B.; Youakim, J.M.; Owen, R.; Stankovic, S.; Tomkinson, E.B.; McDermid, J.; Ocal, D.; Testad, I.; Qayyum, M.A.; Kemos’, P.; Borejko, O.; Megalogeni, M.; Brookes, E.V.; Petrava, A.; Da Silva, M.; Nunez, K. Evaluation of the safety, tolerability, and efficacy of pimavanserin versus placebo in patients with Alzheimer’s disease psychosis: A phase 2, randomised, placebo-controlled, double-blind study. Lancet Neurol., 2018, 17(3), 213-222.
[http://dx.doi.org/10.1016/S1474-4422(18)30039-5] [PMID: 29452684]
[23]
2016 Alzheimer’s disease facts and figures. Alzheimers Dement., 2016, 12(4), 459-509.
[http://dx.doi.org/10.1016/j.jalz.2016.03.001] [PMID: 27570871]
[24]
Kales, H.C.; Gitlin, L.N.; Lyketsos, C.G. Assessment and management of behavioral and psychological symptoms of dementia. BMJ, 2015, 350, h369.
[http://dx.doi.org/10.1136/bmj.h369]
[25]
Porsteinsson, A.P.; Drye, L.T.; Pollock, B.G.; Devanand, D.P.; Frangakis, C.; Ismail, Z.; Marano, C.; Meinert, C.L.; Mintzer, J.E.; Munro, C.A.; Pelton, G.; Rabins, P.V.; Rosenberg, P.B.; Schneider, L.S.; Shade, D.M.; Weintraub, D.; Yesavage, J.; Lyketsos, C.G. Effect of citalopram on agitation in Alzheimer disease: The CitAD randomized clinical trial. JAMA, 2014, 311(7), 682-691.
[http://dx.doi.org/10.1001/jama.2014.93] [PMID: 24549548]
[26]
Brodaty, H.; Ames, D.; Snowdon, J.; Woodward, M.; Kirwan, J.; Clarnette, R.; Lee, E.; Lyons, B.; Grossman, F. A randomized placebo-controlled trial of risperidone for the treatment of aggression, agitation, and psychosis of dementia. J. Clin. Psychiatry, 2003, 64(2), 134-143.
[http://dx.doi.org/10.4088/JCP.v64n0205] [PMID: 12633121]
[27]
Schneider, L.S.; Tariot, P.N.; Dagerman, K.S.; Davis, S.M.; Hsiao, J.K.; Ismail, M.S.; Lebowitz, B.D.; Lyketsos, C.G.; Ryan, J.M.; Stroup, T.S.; Sultzer, D.L.; Weintraub, D.; Lieberman, J.A. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer’s disease. N. Engl. J. Med., 2006, 355(15), 1525-1538.
[http://dx.doi.org/10.1056/NEJMoa061240] [PMID: 17035647]
[28]
Schneider, L.S.; Dagerman, K.S.; Insel, P. Risk of death with atypical antipsychotic drug treatment for dementia: Meta-analysis of randomized placebo-controlled trials. JAMA, 2005, 294(15), 1934-1943.
[http://dx.doi.org/10.1001/jama.294.15.1934] [PMID: 16234500]
[29]
Kales, H.C.; Gitlin, L.N.; Lyketsos, C.G. Management of neuropsychiatric symptoms of dementia in clinical settings: Recommendations from a multidisciplinary expert panel. J. Am. Geriatr. Soc., 2014, 62(4), 762-769.
[http://dx.doi.org/10.1111/jgs.12730] [PMID: 24635665]
[30]
Liu, S.; Li, C.; Shi, Z.; Wang, X.; Zhou, Y.; Liu, S.; Liu, J.; Yu, T.; Ji, Y. Caregiver burden and prevalence of depression, anxiety and sleep disturbances in Alzheimer’s disease caregivers in China. J. Clin. Nurs., 2017, 26(9-10), 1291-1300.
[http://dx.doi.org/10.1111/jocn.13601] [PMID: 27681477]
[31]
Wong, W. Economic burden of Alzheimer disease and managed care considerations. Am. J. Manag. Care, 2020, 26(8), S177-S183.
[PMID: 32840331]
[32]
FDA. Public Health Advisory: Deaths with antipsychotics in elderly patients with behavioral disturbances. 2015. Available from: http://www.fda.gov/Drugs/DrugSafety/PublicHealthAdvisories/ucm053171.htm
[33]
Brodaty, H.; Arasaratnam, C. Meta-analysis of nonpharmacological interventions for neuropsychiatric symptoms of dementia. Am. J. Psychiatry, 2012, 169(9), 946-953.
[http://dx.doi.org/10.1176/appi.ajp.2012.11101529] [PMID: 22952073]
[34]
Leng, M.; Zhao, Y.; Xiao, H.; Li, C.; Wang, Z. Internet-based supportive interventions for family caregivers of people with dementia: Systematic review and meta-analysis. J. Med. Internet Res., 2020, 22(9), e19468.
[http://dx.doi.org/10.2196/19468] [PMID: 32902388]
[35]
Ayalon, L.; Gum, A.M.; Feliciano, L.; Areán, P.A. Effectiveness of nonpharmacological interventions for the management of neuropsychiatric symptoms in patients with dementia: A systematic review. Arch. Intern. Med., 2006, 166(20), 2182-2188.
[http://dx.doi.org/10.1001/archinte.166.20.2182] [PMID: 17101935]
[36]
Chenoweth, L.; King, M.T.; Jeon, Y.H.; Brodaty, H.; Stein-Parbury, J.; Norman, R.; Haas, M.; Luscombe, G. Caring for Aged Dementia Care Resident Study (CADRES) of person-centred care, dementia-care mapping, and usual care in dementia: A cluster-randomised trial. Lancet Neurol., 2009, 8(4), 317-325.
[http://dx.doi.org/10.1016/S1474-4422(09)70045-6] [PMID: 19282246]
[37]
Ballard, C.; Corbett, A. Agitation and aggression in people with Alzheimer’s disease. Curr. Opin. Psychiatry, 2013, 26(3), 252-259.
[http://dx.doi.org/10.1097/YCO.0b013e32835f414b] [PMID: 23528917]
[38]
Yury, C.A.; Fisher, J.E. Meta-analysis of the effectiveness of atypical antipsychotics for the treatment of behavioural problems in persons with dementia. Psychother. Psychosom., 2007, 76(4), 213-218.
[http://dx.doi.org/10.1159/000101499] [PMID: 17570959]
[39]
Jin, B.; Liu, H. Comparative efficacy and safety of therapy for the behavioral and psychological symptoms of dementia: A systemic review and Bayesian network meta-analysis. J. Neurol., 2019, 266(10), 2363-2375.
[http://dx.doi.org/10.1007/s00415-019-09200-8] [PMID: 30666436]
[40]
Azermai, M.; Petrovic, M.; Elseviers, M.M.; Bourgeois, J.; Van Bortel, L.M.; Vander Stichele, R.H. Systematic appraisal of dementia guidelines for the management of behavioural and psychological symptoms. Ageing Res. Rev., 2012, 11(1), 78-86.
[http://dx.doi.org/10.1016/j.arr.2011.07.002] [PMID: 21856452]
[41]
Van Leeuwen, E.; Petrovic, M.; van Driel, M.L.; De Sutter, A.I.; Vander Stichele, R.; Declercq, T.; Christiaens, T. Withdrawal versus continuation of long-term antipsychotic drug use for behavioural and psychological symptoms in older people with dementia. Cochrane Database Syst. Rev., 2018, 3(3), CD007726.
[PMID: 29605970]
[42]
Hermida, A.P.; Tang, Y.L.; Glass, O.; Janjua, A.U.; McDonald, W.M. Efficacy and safety of ECT for Behavioral and Psychological Symptoms of Dementia (BPSD): A retrospective chart review. Am. J. Geriatr. Psychiatry, 2020, 28(2), 157-163.
[PMID: 31668364]
[43]
Tampi, R.R.; Tampi, D.J.; Young, J.; Hoq, R.; Resnick, K. The place for electroconvulsive therapy in the management of behavioral and psychological symptoms of dementia. Neurodegener. Dis. Manag., 2019, 9(6), 283-288.
[http://dx.doi.org/10.2217/nmt-2019-0018] [PMID: 31701804]
[44]
Rao, V.; Lyketsos, C.G. The benefits and risks of ECT for patients with primary dementia who also suffer from depression. Int. J. Geriatr. Psychiatry, 2000, 15(8), 729-735.
[http://dx.doi.org/10.1002/1099-1166(200008)15:8<729:AID-GPS193>3.0.CO;2-A] [PMID: 10960885]
[45]
Hausner, L.; Damian, M.; Sartorius, A.; Frölich, L. Efficacy and cognitive side effects of electroconvulsive therapy (ECT) in depressed elderly inpatients with coexisting mild cognitive impairment or dementia. J. Clin. Psychiatry, 2011, 72(1), 91-97.
[http://dx.doi.org/10.4088/JCP.10m05973gry] [PMID: 21208587]
[46]
Regenold, W.T.; Noorani, R.J.; Piez, D.; Patel, P. Nonconvulsive electrotherapy for treatment resistant unipolar and bipolar major depressive disorder: A proof-of-concept trial. Brain Stimul., 2015, 8(5), 855-861.
[http://dx.doi.org/10.1016/j.brs.2015.06.011] [PMID: 26187603]
[47]
Vacas, S.M.; Stella, F.; Loureiro, J.C.; Simões do Couto, F.; Oliveira-Maia, A.J.; Forlenza, O.V. Noninvasive brain stimulation for behavioural and psychological symptoms of dementia: A systematic review and meta-analysis. Int. J. Geriatr. Psychiatry, 2019, 34(9), 1336-1345.
[http://dx.doi.org/10.1002/gps.5003] [PMID: 30246461]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy